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Abstract 
Paralytic  ileus  is  a  severe  complication
resulting from a variety of disorders. It occurs
most commonly in patients with serious under-
lying  medical  or  surgical  conditions.  Prompt
diagnosis  and  appropriate  management  may
improve the outcome. We describe 2 cases of
onco-hematologic patients who presented this
complication after intensive chemotherapy.
Introduction
Paralytic ileus is a gastrointestinal motility
disorder.  It  is  rare  in  childhood,  but  severe
complications result from a variety of disor-
ders.1,2 This condition results in colonic atony
deriving  from  an  imbalance  in  autonomic
bowel innervation. Patients with trauma, elec-
trolyte  disturbances,  medications  affecting
gastrointestinal motility and sepsis, are pre-
disposed  to  its  development.  The  principal
ileus symptoms are abdominal pain and dis-
tention,  constipation,  failure  to  pass  gas  or
stool, and vomiting. Diagnosis is based on clin-
ical  presentation  with  X-ray  evidence  of
marked colonic dilatation in the absence of a
mechanical  obstruction.  Without  treatment,
the patient’s general conditions rapidly worsen
until dehydration and shock.
We  describe  2  cases  of  onco-hematologic
patients who presented this acute complica-
tion after intensive chemotherapy.
Case #1
VG is a 5-year old girl with a non-Hodgkin’s
abdominal lymphoma which was diagnosed in
March 2011 by abdominal surgery for intestin-
al invagination. She was enrolled on the AIEOP
(Italian  Association  of  Pediatric  Hematology
Oncology)  LNH  97  protocol.  At  the  end  of  a
chemotherapy cycle, in disease remission, she
developed severe abdominal pain and disten-
sion  with  constipation,  vomiting,  and  fever.
Blood  tests  showed  an  increase  in  absolute
leukocyte  number  and  C-reactive  protein.
Intestinal  pseudo-obstruction  was  confirmed
both clinically and by X-ray (Figure 1). Broad-
spectrum  antibiotic  therapy  (meropenem,
metronidazole,  vancomicin,  fluconazol),  a
nasogastric  decompression  and  parenteral
nutrition were performed. However, two days
later,  her  general  condition  worsened  with
aplasia  (PMN  130/mmc),  severe  abdominal
pain,  distension,  hyponatremia  and  fever.
Therapy with G-CSF was started. An abdominal
computed tomography scan (CT) revealed sig-
nificant  cecal  dilatation  without  mechanical
obstruction with residual fecal loading.
Therefore,  four  days  after  the  end  of
chemotherapy, she underwent surgery with an
intestinal resection for ileitis with a pseudo-
volvolus. Ileostomy was not performed because
important  mucosal  damage  made  surgery
impossible. The hystological examination was
negative  for  the  baseline  disease.  Cultural
specimens were negative. Only urine culture
was positive for E. coli ESBL positive. Her gen-
eral condition gradually improved over the fol-
lowing  days.  Supportive  therapy  was,  there-
fore, continued. 
Six days after surgery, her condition wors-
ened again with fever, desaturation and gastric
pain.  Chest  X-ray  showed  a  bilateral  pleural
effusion. The girl was transferred to the inten-
sive care unit with invasive ventilation sup-
port. Antibiotic therapy was changed with col-
imicina, cefepime and linezolid. Her general
condition  was  still  poor.  Maternal  leukocyte
infusion was carried out. Over the following
days, her clinical condition improved. Six days
later,  she  was  extubated  with  no  recurrent
abdominal pain or fever and normal leukocyte
count. Enteral nutrition was gradually restart-
ed without any complications. She presented
regular bowel function. Five days later, 32 days
after onset, she was discharged from hospital
in good general condition. 
She  continued  the  chemotherapy  protocol
until July 2011. She is now in good general
condition in complete disease remission. 
Case #2
GM was diagnosed at the age of 18 with a B-
cell acute lymphoblastic leukemia (ALL), cen-
tral  nervous  system  (CNS)  negative,  one
month after traumatic abdominal injuries due
to a car accident. He started treatment accord-
ing to the AIEOP LLA R 2006 protocol with good
disease response (blasts<1000/UL) after eight
days. 
Induction therapy was immediately compli-
cated  by  asthenia,  nausea,  and  constipation
treated with antiemetic, oral laxatives and rec-
tal enemas with transient relief. After 3 doses
of  VCR  (vincristine),  he  developed  severe
abdominal  pain  with  marked  constipation
associated  with  weight  loss.  X-ray  of  the
abdomen  showed  gas/fluid-levels  scattered
throughout the abdomen. Blood count showed
pancytopenia (PMN 90/mmc). Parenteral ther-
apy was started with hydratation, antibiotics
(piperacilline/tazobactam,  amikacine)  and
antifungal  (fluconazol).  Rectal  enemas  still
had  transient  relief.  Stool  cultural  examina-
tions  were  negative,  C-reactive  protein  was
slightly raised.
Five days later he presented severe abdomi-
nal and left scapular pain with nausea, vomit-
ing  and  fever.  Physical  examination  showed
abdominal  distention.  The  X-ray  of  the
abdomen  showed  free  gas  in  the  abdominal
cavity  (left  hypochondrium).  According  the
suspicious of intestinal perforation due to par-
alitic ileus and mucositis, the patient under-
went emergency surgery. Perforations in the
ileo cecal valve and cecum end were found and
repaired, associated with an important dilata-
tion  in  the  proximal  ileus  and  a  temporary
ileostomy was needed. The peritoneal culture
was  positive  for  Enterococcus  faecalis and
Prevotella oralis.
After surgery, the leukocyte count increased
and the patient’s condition improved. Broad-
spectrum  antibiotics  (meropenem,  van-
comicin,  metronidazole),  antifungal  therapy
(fluconazol),  and  continuous  hydration  with
close monitoring of electrolytes were contin-
ued. He was transferred to the Pediatric Onco-
Hematology Division 12 days after surgery. At
Day 46 a bone marrow showed the remission
of disease. On Day 58, after an improvement in
his  general  clinical  condition,  chemotherapy
was restarted. 
Enteral  nutrition  was  gradually  restarted
and bowel function reestablished. He was dis-
charged  from  hospital  two  weeks  later  with
ileostomy. He is now in good clinical condition
Pediatric Reports 2012; volume 4:e3
Correspondence:  Carraro  Francesca,  Onco-
Hematology,  Stem  Cell  Transplantation  and
Cellular  Therapy  Division,  Regina  Margherita
Children’s Hospital, Turin, Italy.
E-mail: francesca.carraro80@libero.it
Key  words:  paralitic  ileus,  onco-hematologic
patients, pediatric.
Received for publication: 3 November 2011.
Revision received: 15 November 2011.
Accepted for publication: 18 November 2011.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright  F. Carraro et al., 2012
Licensee PAGEPress, Italy
Pediatric Reports 2012; 4:e3
doi:10.4081/pr.2012.e3[Pediatric Reports 2012; 4:e3] [page 11]
in complete disease remission and is continu-
ing chemotherapy.
Discussion 
Paralytic ileus is associated with infections
or disorders of autonomic neuropathy caused
by  chemotherapy  drugs,  such  as  vincristine
and vinblastine or opioid, which depress bowel
peristalsis. 
VCR  gastrointestinal  toxicity  seems  to  be
dose-related and cumulative.3 Co-administra-
tion of several drugs which interfere with VCR
metabolism  and  elimination  can  increase
drug-related toxicity.2,4,5 VCR is metabolized by
the hepatic CYP3A subfamily of enzymes and
then  mainly  eliminated  by  biliary  excretion.
Several polymorphisms of CYP3A5 with vari-
able  phenotypic  expression  have  been
described and might be of importance when
considering the potential implication of drug
interactions. According to this genetic variabil-
ity, in some patients, several drugs, such as
azole antifungals or nifedipine might increase
VCR exposure. Macrolides and steroids have
also been mentioned as interfering with VCR
metabolism, as either inhibitors, inducers, or
both.2,5
However, in pediatric patients, VCR-related
pseudo-obstruction seems to be reversible and
even  allows  chemotherapy  to  be  continued.
The implications of genetic polymorphisms in
the CYP3A and MDR1 genes are not clear or
feasible in all patients.6
There is little awareness of this condition
and a lack of guidance for both diagnosis and
management. Prompt diagnosis and appropri-
ate management of these patients may reduce
the significant morbidity and mortality seen in
this  uncommon  condition.  The  outcome  of
ileus  varies  depending  on  its  cause.1 Initial
management is conservative with bowel rest
and  nasogastric  decompression,  intravenous
fluids and correction of electrolyte imbalance,
cessation  of  medications  affecting  colonic
motility.1,7 Especially  in  onco-hematologic
patients the prompt treatment with broad spec-
trum  antibiotics  and  antifungals  is  recom-
mended to improve the outcome.
Surgical intervention to remove the cause of
ileus  is  necessary  when  the  obstruction  is
complete or the bowel is likely to become gan-
grenous.  The  type  of  surgical  procedure
depends on the condition of the bowel and the
cause  of  the  obstruction.  In  some  cases,
ileostomy  or  colostomy,  either  temporary  or
permanent, may be necessary.1,7
Here we describe 2 oncologic pediatric cases
who  developed  acute  colonic  pseudo-obstruc-
tion  during  intensive  chemotherapy.  Both
patients  underwent  intensive  chemotherapy
cycles with damage to gut mucoses, and alter-
ations  in  bowel  function  during  a  prolonged
bone marrow depression. While in the first case
the previous surgery was a relevant risk factor,
in the second case the high-dose steroid thera-
py caused concomitant gastric mucose damage
and  abdominal  distension  associated  with  a
bowel atony due to VCR. Genetic polymorphisms
were not assessed in our patients. In both cases,
the  prompt  therapy  with  intravenous  fluid,
nasogastric decompression and antibiotic ther-
apy  improved  the  outcome,  although  both
patients  needed  a  multidisciplinary  approach
with  surgery,  carefully  controlled  electrolytic
imbalance and sepsis status.
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Case Report
Figure 1. Intestinal pseudo-obstruction confirmed by X-ray.